Current Concepts in the Management of Relapsed/Refractory Multiple Myeloma: Considerations With Bispecific Anti-BCMA Antibodies
Podcast 1: Management of Multiple Myeloma: Clinical Course and Treatment Options
Post-Test/Evaluation

Questions marked with a * are required

20%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Which of the following options for multiple myeloma are used in patients who have relapsed or not responded to several courses of therapy rather than as initial therapy?

A. Corticosteroids

B. B-cell maturation antigen (BCMA) therapies

C. Proteasome inhibitors

D. Immunomodulatory drugs

Sharon is a 68-year-old woman with multiple myeloma. In the past, she has received an immunomodulatory agent, a proteosome inhibitor, and a combination therapy that incorporated an anti-CD38 antibody. She presents with another relapse. What approach would you take?

A. Keep her current regimen as is

B. Do not consider enrolling the patient in a clinical trial at this time

C. Try another course of a proteosome inhibitor or an immunomodulatory drug

D. Try CAR-T, a bispecific antibody, or a novel agent